Trial Profile
Treatment Free Remission After Combination Therapy With Ruxolitinib Plus Tyrosine Kinase Inhibitors in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed After a Prior Attempt at TKI Discontinuation
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 09 Apr 2024
Price :
$35
*
At a glance
- Drugs Bosutinib (Primary) ; Dasatinib (Primary) ; Imatinib (Primary) ; Nilotinib (Primary) ; Ruxolitinib (Primary)
- Indications Chronic myeloid leukaemia
- Focus Therapeutic Use
- 17 Oct 2023 Planned End Date changed from 1 Jan 2024 to 1 Jan 2025.
- 17 Oct 2023 Planned primary completion date changed from 1 Jan 2024 to 1 Jan 2025.
- 04 Apr 2022 Planned number of patients changed from 41 to 51.